Comparative effectiveness of inebilizumab versus conventional immunotherapies in AQP4-IgG-positive NMOSD: a prospective cohort study with time-varying treatment effects. (PubMed, J Neurol Neurosurg Psychiatry) - Sep 16, 2026 - "Inebilizumab was associated with better relapse and disability outcomes than AZA or MMF. Compared with RTX, inebilizumab was associated with lower ARR, whereas no significant differences were detected in time to first relapse or disability progression."
HEOR • Journal • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
|
|
Chao Quan; Hongmei Tan; Jingzi ZhangBao; Lei Zhou; Qiang Dong; Wenjuan Huang; Xiang Li; Xintong Zhang; Zhouzhou Wang
|